Realising the Next Generation of RNA Therapeutics
Technology Platform
Our platform integrates programmable nucleic acid therapeutics with tissue specific delivery systems which provides unprecedented precision and efficacy. We are developing transformative solutions for high-burden diseases, such as cardiovascular and metabolic disorders, as well as autoimmune conditions. Leveraging Singapore’s world-class clinical expertise in ophthalmology, we are also pushing the boundaries of ocular medicine. In parallel, we are committed to rapid response during pandemics and to address other global health challenges in infectious disease.
Therapeutic Areas
Cardiovascular and Metabolic Diseases: Enabled by ligand directed delivery of RNA therapeutics, targeted modulation of metabolic pathways can be achieved in skeletal muscle, liver, adipose tissue, and heart to restore systemic energy balance.
Infectious Disease Vaccines and Autoimmune Disorders: Immune-silent lipid nanoparticles deliver self-antigens encoded as mRNA together with regulatory cues to induce antigen-specific tolerance. This approach selectively suppresses pathogenic responses while avoiding inflammation, offering a targeted strategy for autoimmune and inflammatory disorders.
Ophthalmology: Ligand-receptor binding mediated uptake enables durable, cell-specific modulation of disease-relevant genes, opening pathways to novel therapeutics for a broad range of ophthalmic conditions.